Acute spondyloarthritis developing during successful treatment with dupilumab for severe atopic dermatitis

Clin Exp Dermatol. 2022 Mar;47(3):592-593. doi: 10.1111/ced.14984. Epub 2021 Dec 9.

Authors

A Raimondo¹, G Guglielmi¹, C Marino², L Ligrone², S Lembo¹

Affiliations

¹ Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Salerno, Italy.
² S. Giovanni di Dio e Ruggi D'Aragona University Hospital, PO Santa Maria Incoronata Dell'Olmo, Cava dè Tirreni, Salerno, Italy.

PMID: 34655234
DOI: 10.1111/ced.14984

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects*
Azetidines / therapeutic use
Dermatitis, Atopic / drug therapy*
Dermatologic Agents / adverse effects*
Dermatologic Agents / therapeutic use
Humans
Janus Kinase 1 / antagonists & inhibitors
Janus Kinase 2 / antagonists & inhibitors
Male
Osteoarthritis, Spine / chemically induced*
Osteoarthritis, Spine / diagnosis
Osteoarthritis, Spine / drug therapy
Purines / therapeutic use
Pyrazoles / therapeutic use
Sulfonamides / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Azetidines
Dermatologic Agents
Purines
Pyrazoles
Sulfonamides
dupilumab
JAK1 protein, human
JAK2 protein, human
Janus Kinase 1
Janus Kinase 2
baricitinib